Development of a new whole blood analog for emergency resuscitation
Consortium for Optimized Integration of Bio-Artificial Blood Components for Adaptive Resuscitation Therapy
This study is testing a new type of artificial blood to see if it can help people in emergencies when regular blood isn’t available, especially during severe bleeding.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 250 (estimated) |
| Ages | 18 Years to 88 Years |
| Sex | All |
| Sponsor | University of Maryland, Baltimore Academic / other |
| Locations | 1 site (Baltimore, Maryland) |
| Trial ID | NCT05756426 on ClinicalTrials.gov |
What this trial studies
This observational study aims to develop a whole blood analog that can be used in situations where traditional banked blood is unavailable or undesirable, particularly in cases of hemorrhage and hemodynamic instability. The study will focus on integrating individual artificial blood components designed to overcome previous failures of blood substitutes, such as dysfunctional oxygen interactions and interference with blood vessel regulation. Data and specimens will be collected from new subjects enrolled at the University of Maryland, Baltimore, to evaluate the performance of these components in mimicking natural blood functionality.
Who should consider this trial
Good fit: Ideal candidates for this study are generally healthy adults aged 18 and older who weigh more than 40 kg.
Not a fit: Patients with ongoing infections, pregnant individuals, or non-English speakers may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a life-saving alternative for patients experiencing severe hemorrhage when conventional blood products are not accessible.
How similar studies have performed: While previous blood substitutes have faced challenges, this approach aims to address those failures, making it a novel and potentially impactful initiative.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subject \>/= 18 years of age * Subject weighs \>40kg (88lbs) * Subject must be generally healthy Exclusion Criteria: * Suspected or diagnosed with ongoing (chronic) or acute infection * Subject is pregnant * Subject is non-english speaking
Where this trial is running
Baltimore, Maryland
- University of Maryland Baltimore (UMB) — Baltimore, Maryland, United States (Recruiting)
Study contacts
- Principal investigator: Stephen Rogers, PhD — University of Maryland, Baltimore
- Study coordinator: Stephen Rogers, PhD
- Email: stephen.rogers@som.umaryland.edu
- Phone: 410-706-7094
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.